#United States #New York #Karyopharm #XPOVIO #cancer therapies

Karyopharm Therapeutics to Present at Jefferies Global Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a notable player in the pharmaceutical sector dedicated to developing innovative cancer treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference set for June 5, 2025. This anticipated event will take place at 3:10 PM ET in New York, NY, where the company's senior management team will provide insights into their latest developments.

As Karyopharm steps onto the stage at the prestigious conference, it seeks to further demonstrate its commitment to advancing therapies for cancer patients worldwide. The live presentation will not only detail the company’s pipeline but will also highlight their flagship drug, XPOVIO® (selinexor), which stands as a first-in-class oral exportin 1 (XPO1) inhibitor aimed at overcoming challenges in oncogenesis caused by nuclear export dysregulation.

About the Conference

The Jefferies Global Healthcare Conference is an annual event that brings together industry leaders, investors, and innovators from the healthcare sector. This conference serves as a platform for companies like Karyopharm to showcase their strategies, pipeline products, and engage with stakeholders regarding current trends and future projections within the healthcare landscape. Attendees can expect in-depth presentations and opportunities for networking and discussions centered on advancing healthcare.

Karyopharm’s presentation will be accessible via a live webcast, which can be found under the “Events & Presentations” section on their investor relations website. For those unable to attend live, the archived version will be available for replay, ensuring that all interested parties can stay informed about the latest updates from Karyopharm.

Karyopharm's Commitment to Innovation

Founded to champion the needs of cancer patients, Karyopharm Therapeutics has made significant strides since its inception, particularly in the domain of oral therapies. The company’s flagship product, XPOVIO®, is approved for use in several oncological settings, showcasing effective treatment options for patients battling multiple myeloma and various forms of cancer. With ongoing studies and a robust pipeline targeting high unmet needs across various oncology indications, Karyopharm is set to redefine treatment paradigms in cancer care.

The company has been recognized for its pioneering efforts across multiple regulatory jurisdictions, receiving approvals not only in the U.S. but also in Europe and China, where XPOVIO® is marketed under the name NEXPOVIO®. Karyopharm’s ongoing research and development efforts reflect its dedication to staying at the forefront of oncology advancements.

Future Prospects

At the conference, Karyopharm's management will discuss future directions, including upcoming clinical trials and pipeline expansions. The firm is on a path to address significant gaps in cancer treatment, specifically focusing on conditions like diffuse large B-cell lymphoma (DLBCL), endometrial cancer, and myelofibrosis. As it forges ahead, industry observers and investors alike are keen to follow Karyopharm's progress and how its innovations will contribute to improving patient outcomes in oncology.

For updates and more information about Karyopharm’s ongoing work and its commitment to research and development in oncological therapies, interested parties can visit the Karyopharm website and follow the company on platforms like LinkedIn and X (formerly Twitter).

In conclusion, Karyopharm Therapeutics’ participation in the Jefferies Global Healthcare Conference underscores its leading role within the pharmaceutical industry and its steadfast commitment to advancing cancer treatment through innovative solutions.